Skip to main content

2 Result(s)

within Ryohei Ogata Remove this filter

and

  1. Article

    Open Access

    Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

    Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-...

    Ryohei Ogata, Emi Kishino, Wataru Saitoh, Yoshikazu Koike… in Breast Cancer (2021)

    Download PDF (1021 KB) View Article

  2. No Access

    Article

    Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells

    A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib, has been used to treat patients with estrogen receptor (ER)-positive (+) and human epidermal growth factor receptor (HER) 2-negative (−) advanced bre...

    Emi Kishino, Ryohei Ogata, Wataru Saitoh, Yoshikazu Koike, Yusuke Ohta… in Breast Cancer (2020)